Baseline vs. on-treatment heart failure with preserved ejection fraction (HFpEF) in a real world cardio-oncology clinic: observational analysis of cancer therapy-related cardiovascular toxicity incidence and cancer treatment implications - Takeaways - MDSpire

Baseline vs. on-treatment heart failure with preserved ejection fraction (HFpEF) in a real world cardio-oncology clinic: observational analysis of cancer therapy-related cardiovascular toxicity incidence and cancer treatment implications

  • By

  • Berlinde von Kemp

  • Xavier Galloo

  • Bram Roosens

  • Bart Neyns

  • Rik Schots

  • Mark De Ridder

  • Bernard Cosyns

  • June 9, 2026

  • 0 min

Share

  • 1

    Pre-existing HFpEF in cancer patients is associated with higher mortality compared to those without heart failure.

  • 2

    Patients with pre-existing HFpEF experienced more HFpEF events during cancer treatment, despite similar CTR-CVT incidence.

  • 3

    Older age, female sex, hypertension, and previous arrhythmias are predictors for developing HFpEF events in cancer patients.

  • 4

    Current guidelines do not adequately address HFpEF in cancer therapy-related cardiac dysfunction definitions.

  • 5

    The study highlights the need for improved risk stratification tools to include HFpEF in cancer patient evaluations.

Original Source(s)

Baseline vs. on-treatment heart failure with preserved ejection fraction (HFpEF) in a real world cardio-oncology clinic: observational analysis of cancer therapy-related cardiovascular toxicity incidence and cancer treatment implications

  • by Berlinde von Kemp, Xavier Galloo, Bram Roosens, Bart Neyns, Rik Schots, Mark De Ridder, Bernard Cosyns

  • June 9, 2026

Related Content

Understanding cardiac toxicity and immune responses to thoracic radiation therapy in non-small cell lung cancer – implications for future research

Breaking the Biomarker Bottlenecks: Part 2

Industry leaders from AstraZeneca, Leica Biosystems, and Danaher share their insights on AI’s power to democratize access to precision medicine

  • February 16, 2026

  • 9 min
Metabolomics discover distinct metabolite profiles in children with different airway allergic diseases